Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Virpax Pharmaceuticals, Inc. (VRPX)
|
Add to portfolio |
|
|
|
| Price: |
$3.38
| | Metrics |
| OS: |
11.7
|
M
| |
-124
|
% ROE
|
| Market cap: |
$39.6
|
M
| |
-131
|
% ROIC
|
|
Net cash:
|
|
| |
|
|
|
EV:
|
$39.6
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($16.1)
|
M
| |
|
|
|
EBIT
|
($16.1)
|
M
| |
|
|
| EPS |
($1.30)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 |
| Revenues | 22.6 | 13.5 | 0.0 | 0.0 | 0.0 |
| Revenue growth | 68.0% | | | | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 22.6 | 13.5 | 0.0 | 0.0 | 0.0 |
| Gross margin | 100.0% | 100.0% | | | |
| Research and development | 10.8 | 4.8 | 1.3 | 0.6 | 1.1 |
| General and administrative | 11.7 | 8.1 | 2.9 | 2.6 | 1.5 |
| EBIT | -21.7 | -11.5 | -4.2 | -3.2 | -2.6 |
| EBIT margin | -96.0% | -85.6% | | | |
| Pre-tax income | -21.7 | -12.1 | -4.3 | -3.3 | -2.6 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -21.7 | -12.1 | -4.3 | -3.3 | -2.6 |
| Net margin | -95.8% | -89.6% | | | |
| |
| Diluted EPS | ($1.85) | ($1.81) | ($1.40) | ($1.13) | ($0.93) |
| Shares outstanding (diluted) | 11.7 | 6.7 | 3.1 | 2.9 | 2.8 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|